Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment

被引：0
|
作者：
Sands, Bruce E. [1 ]
Kobayashi, Taku [2 ]
Wu, Jianmin [3 ]
Wang, Isabella Yali [3 ]
Zhu, Baojin [3 ]
Redondo, Isabel [4 ]
Peyrin-Biroulet, Laurent [5 ,6 ]
Walsh, Alissa [7 ]
Magro, Fernando [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Kitasato Univ, Kitasato Inst Hosp, Minato City, Tokyo, Japan
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Eli Lilly & Co, Lisbon, Portugal
[5] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vandoeuvre Les Nancy, France
[6] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[7] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[8] Univ Porto, Porto, Portugal
[9] Ctr Hosp, Porto, Portugal
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035164.22459.94
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1449
引用
收藏
页码：S1042 / S1043
页数：2
相关论文
共 50 条
  • [21] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Hibi, Toshifumi
    D'Haens, Geert R.
    Tuttle, Jay
    Krueger, Kathryn A.
    Friedrich, Stuart
    Durante, Michael
    Arora, Vipin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
  • [22] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
    Sandborn, W. J.
    Sands, B.
    Kobayashi, T.
    Tuttle, J.
    Schmitz, J.
    Durante, M.
    Higgs, R.
    Canavan, J. B.
    Siegel, R.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
  • [23] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [24] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
    Abraham, Bincy P.
    Longman, Randy
    Katsanos, Konstantinos
    Lee, Scott D.
    Kobayashi, Taku
    Bettenworth, Dominik
    Korman, Louis
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Torres, Joana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063
  • [25] Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
    Rubin, David T.
    Cree, Bruce A. C.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Cohen, Jeffrey A.
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S680 - S680
  • [26] Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis
    Cree, Bruce A. C.
    Danese, Silvio
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Petersen, AnnKatrin
    Sheffield, James K.
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Lublin, Fred D.
    Rubin, David T.
    Cohen, Jeffrey A.
    NEUROLOGY, 2023, 100 (17)
  • [27] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [28] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    GASTROENTEROLOGY, 2024, 166 (03) : S60 - S60
  • [29] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
    Ignacio Fernandez-Blanco, J.
    Fernandez-Diaz, Guillermo
    Cara, Carlos
    Vera, Maria I.
    Olivares, David
    Taxonera, Carlos
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 731 - 737
  • [30] Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab
    Magro, Fernando
    Lopes, Susana Isabel
    Lopes, Joanne
    Portela, Francisco
    Cotter, Jose
    Lopes, Sandra
    Moreira, Maria Joao
    Lago, Paula
    Peixe, Paula
    Albuquerque, Andreia
    Rodrigues, Susana
    Silva, Mario Rui
    Monteiro, Pedro
    Lopes, Castro
    Monteiro, Lucilia
    Macedo, Guilherme
    Veloso, Luis
    Camila, Claudia
    Afonso, J.
    Geboes, Karel
    Carneiro, Fatima
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (12): : 1407 - 1416
12345